Skip to main content

Table 1 Patient demographics and clinical characteristics

From: Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib

Parameter No.
Sex  
Male 22
Female 15
Median age, years 58
Range 27-77
ECOG performance status  
0 20
1 17
Tumor biopsy sites  
Liver 15
Abdominal wall 9
Rectum/vaginal wall 4
Scalp 2
Lymph node 5
Prior lines of treatment  
2-3 18 (51%)
≥4 17 (49%)
Prior treatment  
Bevacizumab 15 (43%)
Cetuximab 15 (43%)
Baseline organ function  
AST (U/L) 34.6 ± 22.4
ALT (U/L) 23.5 ± 10.9
Total bilirubin (μmol/L) 10.1 ± 5.8
Creatinine (μmol/L) 66.9 ± 27.0
  1. 37 patients screened; 35 commenced therapy, 2 failed screening.
  2. 8 patients did not complete cycle 2 for tumour biopsy and evaluation of response.
  3. 11 patients did not have second biopsy.